Post Content
Quick Read
-
Cardinal Health (CAH) garnered an Outperform initiation from William Blair with a distribution platform that creates a durable competitive moat, generating 19% revenue growth to $65.63B last quarter.
-
Notably, William Blair launched its coverage of Cardinal Health and McKesson (MCK) ahead of their earnings reports, betting that the pharma distribution duopoly will benefit from demographic demand and GLP-1 drug distribution volume as they pivot toward higher-margin specialty services.
-
The analyst who called NVIDIA in 2010 just named his top 10 stocks and Cardinal Health wasn’t one of them. Get them here FREE.
William Blair launched coverage of Cardinal Health (NYSE:CAH) with an Outperform rating today, framing the pharma distributor as a durable franchise with specialty-led upside. The firm simultaneously initiated McKesson (NYSE:MCK) at Outperform, a dual launch that signals conviction in the U.S. drug-distribution oligopoly. For prudent investors, the call tightens an already constructive sell-side picture on a name that has quietly compounded.
Cardinal Health stock has returned 48% over the past year and 240% over five years, reframing the “stealth compounder” thesis in real numbers. Those returns underscore why William Blair sees durable upside ahead.
|
Ticker |
Company |
Firm |
Action |
Old Rating |
New Rating |
Old Target |
New Target |
|---|---|---|---|---|---|---|---|
|
CAH |
Cardinal Health |
William Blair |
Initiation |
N/A |
Outperform |
N/A |
Not disclosed |
|
MCK |
McKesson |
William Blair |
Initiation |
N/A |
Outperform |
N/A |
Not disclosed |
The Analyst’s Case
William Blair argues that Cardinal Health’s distribution platform creates a “durable competitive moat” that supports “high-growth specialty upside.” The firm cites the scale of Cardinal Health’s distribution capabilities and the breadth of non-distribution services as key advantages.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and Cardinal Health wasn’t one of them. Get them here FREE.
The same thesis underpins the McKesson initiation, where William Blair flagged demographic tailwinds and rising adoption of specialty medicines. The synthesis: an oligopolistic structure (Cardinal Health, McKesson, and Cencora (NYSE:COR)) is well positioned for a favorable demand backdrop.
Company Snapshot
Cardinal Health carries a market capitalization of $47.6 billion and trades at 18x forward earnings. The latest quarter delivered revenue of $65.63 billion, a 19% increase, with non-GAAP EPS of $2.63 beating consensus.
CEO Jason Hollar pointed to “at least double-digit segment profit growth across all five of our operating segments” and raised fiscal 2026 EPS guidance to $10.15 to $10.35. The Solaris Health urology platform and Advanced Diabetes Supply deals deepen the specialty mix.
Why the Move Matters Now
Cardinal Health reports Q3 FY2026 results on April 30, making William Blair’s launch a pre-earnings statement. McKesson follows on May 7, while CVS Health (NYSE:CVS) reports on May 6, offering a useful contrast between pure-play distributors and integrated payers.
The company’s valuation gives the bull case room to breathe. Cardinal Health’s forward P/E ratio of 18x sits below McKesson’s 19x, while the consensus 12-month target sits at $248.27 against Cardinal Health stock’s current $205 level. For deeper context on the sector setup, see this recent healthcare distribution outlook.
What It Means for Your Portfolio
The bull case rests on demographic demand, GLP-1 distribution volume, and the specialty pivot Cardinal Health is executing across urology, at-home solutions, and nuclear precision health. Operating cash flow of $686 million last quarter (up 272%) funds buybacks and the 1% dividend.
The bear case is substantial. Cardinal Health’s razor-thin operating margins of 1%, a DOJ Anti-Kickback Statute investigation, GMPD tariff exposure, and potential GLP-1 commoditization all weigh on the long thesis.
For prudent investors, William Blair’s CAH stock upgrade to Outperform aligns with a “Moderate Buy” consensus across 17 analysts. Watch for whether the April 30 earnings release validates the specialty-led growth narrative that anchors the stealth compounder thesis.
The analyst who called NVIDIA in 2010 just named his top 10 AI stocks
This analyst’s 2025 picks are up 106% on average. He just named his top 10 stocks to buy in 2026. Get them here FREE.
Terms and Privacy Policy